200 related articles for article (PubMed ID: 29985231)
1. Perhaps it's not the platelet: Ristocetin uncovers the potential role of von Willebrand factor in impaired platelet aggregation following traumatic brain injury.
Kornblith LZ; Robles AJ; Conroy AS; Hendrickson CM; Calfee CS; Fields AT; Callcut RA; Cohen MJ
J Trauma Acute Care Surg; 2018 Nov; 85(5):873-880. PubMed ID: 29985231
[TBL] [Abstract][Full Text] [Related]
2. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
Weiss HJ; Sussman II
Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium.
Stel HV; Sakariassen KS; Scholte BJ; Veerman EC; van der Kwast TH; de Groot PG; Sixma JJ; van Mourik JA
Blood; 1984 Jun; 63(6):1408-15. PubMed ID: 6426553
[TBL] [Abstract][Full Text] [Related]
4. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
Miller JL; Kupinski JM; Castella A; Ruggeri ZM
J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
[TBL] [Abstract][Full Text] [Related]
6. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
Kao KJ; Pizzo SV; McKee PA
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities of factor VIII and platelet aggregation--use of ristocetin in diagnosing the von Willebrand syndrome.
Weiss HJ
Blood; 1975 Mar; 45(3):403-12. PubMed ID: 1078779
[TBL] [Abstract][Full Text] [Related]
8. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers.
Weinstein M; Vosburgh E; Phillips M; Turner N; Chute-Rose L; Moake J
Blood; 1991 Nov; 78(9):2291-8. PubMed ID: 1932745
[TBL] [Abstract][Full Text] [Related]
9. Platelet-collagen interaction: inhibition by ristocetin and enhancement by von Willebrand factor-platelet binding.
LaDuca FM; Bettigole RE; Bell WR; Robson EB
Blood; 1986 Oct; 68(4):927-37. PubMed ID: 3489493
[TBL] [Abstract][Full Text] [Related]
10. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
[TBL] [Abstract][Full Text] [Related]
11. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets.
Phillips MD; Moake JL; Nolasco L; Turner N
Blood; 1988 Dec; 72(6):1898-903. PubMed ID: 3264193
[TBL] [Abstract][Full Text] [Related]
12. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
13. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
Casonato A; Cattini MG; Soldera C; Marcato S; Sartorello F; Pontara E; Pagnan A
J Lab Clin Med; 2004 Nov; 144(5):254-9. PubMed ID: 15570243
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
[TBL] [Abstract][Full Text] [Related]
15. Structure and function of the von Willebrand factor A1 domain: analysis with monoclonal antibodies reveals distinct binding sites involved in recognition of the platelet membrane glycoprotein Ib-IX-V complex and ristocetin-dependent activation.
De Luca M; Facey DA; Favaloro EJ; Hertzberg MS; Whisstock JC; McNally T; Andrews RK; Berndt MC
Blood; 2000 Jan; 95(1):164-72. PubMed ID: 10607699
[TBL] [Abstract][Full Text] [Related]
16. Hemostasis, platelet function and serotonin in acute and chronic renal failure.
Malyszko J; Malyszko JS; Pawlak D; Pawlak K; Buczko W; Mysliwiec M
Thromb Res; 1996 Sep; 83(5):351-61. PubMed ID: 8873344
[TBL] [Abstract][Full Text] [Related]
17. The effect of ex vivo anticoagulants on whole blood platelet aggregation.
Kalb ML; Potura L; Scharbert G; Kozek-Langenecker SA
Platelets; 2009 Feb; 20(1):7-11. PubMed ID: 19172515
[TBL] [Abstract][Full Text] [Related]
18. Comparison of thrombin and ristocetin in the interaction between von Willebrand factor and platelets.
Harrison RL; McKee PA
Blood; 1983 Aug; 62(2):346-53. PubMed ID: 6307433
[TBL] [Abstract][Full Text] [Related]
19. Platelet-collagen adhesion enhances platelet aggregation induced by binding of VWF to platelets.
Laduca FM; Bell WR; Bettigole RE
Am J Physiol; 1987 Nov; 253(5 Pt 2):H1208-14. PubMed ID: 3500650
[TBL] [Abstract][Full Text] [Related]
20. Platelet-binding of the von Willebrand factor.
Green D; Muller HP
Thromb Haemost; 1978 Jun; 39(3):689-94. PubMed ID: 309191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
